Biomarin prepares for European approval of Ascendis competitor
![The EMA HQ in Amsterdam. | Photo: Rob Acket/EMA](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13165754.ece/ALTERNATES/schema-16_9/doc7gv5votxe8yqu29meqy.jpg)
US biotech firm Biomarin ended the second quarter with a revenue growth of 17 percent compared to the same period last year. The result was USD 501.7m.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
FDA extends review period for Ascendis Pharma's first drug
For subscribers